Argomenti trattati
The annual gathering organized by The Genome Partnership, known as AGBT, once again drew the genomics community together for a concentrated burst of news and scientific exchange. The meeting opened in Orlando with a mix of ceremony and science: award presentations, lively talks, and vendor suites brimming with product reveals. Conference-goers navigated travel hiccups and unexpected weather while focusing on developments that will influence research and diagnostics across the year. In this report, I summarize the most notable awards, instrument launches, and technology themes that dominated conversations and presentations.
Across talks and exhibitor sessions, a few themes stood out: dramatic moves in next-generation sequencing, the accelerating maturity of spatial biology, and an ongoing push toward integrated multiomics workflows. The meeting paired high-level science—such as new biological models presented on stage—with practical updates about instrument pricing, throughput, and timelines. Throughout the event, speakers and companies emphasized reproducibility, scalability, and how new tools will be applied to disease research, large cohorts, and organoid systems.
Awards and opening session highlights
The opening session combined science and recognition. Former NHGRI director Eric Green, MD, PhD, received the Distinguished Service Award from The Genome Partnership during the meeting’s launch. Green, now serving as chief medical officer at Illumina, has been a long-time contributor to the program and was acknowledged for his years of leadership. The session also included an engaging biology talk by Emma Teeling, PhD, on bats as models for disease resistance and extended healthspan—material that captured attention beyond the typical technology-centric crowd. These moments set a tone that the meeting values both innovation and scientific insight.
Sequencing innovations and commercial moves
New instruments and pricing details
Several companies used the AGBT timeframe to disclose new sequencing systems and pricing models. Ultima Genomics unveiled the UG 200 single-wafer and UG 200 Ultra dual-wafer instruments, positioned as higher-throughput and lower-cost successors to the UG 100, which launched in 2026. Roche revealed additional specifics about its SBX nanopore system, the Axelios: a list price for the instrument at $750,000 and consumable pricing that includes a whole genome cost of $150 in duplex mode and a simplex per-read metric of $0.06 per million reads, with availability slated for the upcoming summer. Meanwhile, Element Biosciences previewed the VITARI high-throughput benchtop system and confirmed shipments will begin in the second half of 2026.
Corporate deals and strategic transitions
Industry structure also shifted: Complete Genomics disclosed an agreement to become a subsidiary of Swiss Rockets AG, moving away from prior ownership ties. Such transactions signal how strategic ownership can influence access to markets and future product focus. Across the exhibitor floor, companies emphasized product maturity: shorter development cycles, iterative improvements based on field feedback, and clearer roadmaps for customers seeking to scale genomic studies.
Spatial biology, multiomics, and the rise of 3D analysis
Platforms tackling organoids and 3D reconstruction
Spatial approaches were a major focus, with vendors expanding panels, workflows, and analysis tools. Vizgen showcased updates to MERSCOPE Ultra, including broader predesigned panels and new customization options that enable spatial interrogation of organoids—an area historically difficult for spatial methods. Boston newcomer Stellaromics introduced Pyxa, billed as a commercially available 3D spatial imager and a clear nudge for the field to move beyond two-dimensional analysis. Bruker Spatial Biology launched CellScape for spatial proteomics and PaintScape for 3D genome visualization while adding a mouse whole-transcriptome offering with 64 proteins on the CosMx platform.
Multiomics integrations and novel assays
The meeting also amplified multiomic integration: BD Biosciences (now Waters) promoted the Rhapsody System roadmap for multimodal single-cell profiling, and newly founded companies highlighted niche solutions—Syndex Bio with its mcPCR for simultaneous DNA and methylation copying, and Codetta Bio commercializing the Concerto system to detect DNA, RNA, and protein markers in one run. Innovations such as Cellanome’s CellCage, which tracks cellular history while sampling transcriptomes, and Volta Labs expanding its Callisto platform through partnerships underscore how developers are connecting temporal, spatial, and molecular layers of biology.
Conclusions and forward view
AGBT remains a fertile ground for announcements that set agendas across genomics and spatial biology. From instrument price transparency and shipping timelines to new products enabling 3D spatial analysis and integrated multiomics, the meeting highlighted both incremental and disruptive advances. The momentum does not stop when attendees return home: these introductions create pipelines of validation studies, customer feedback, and application notes that will define the next waves of adoption. For researchers and organizations tracking technology, the key takeaway is that innovation is steady and increasingly focused on scalability, cost, and biologically meaningful integration.